| BRAFV600E Promotes Invasiveness of Thyroid Cancer Cells through Nuclear Factor κB Activation I Palona, H Namba, N Mitsutake, D Starenki, A Podtcheko, I Sedliarou, ... Endocrinology 147 (12), 5699-5707, 2006 | 153 | 2006 |
| Induction of thyroid cancer cell apoptosis by a novel nuclear factor κB inhibitor, dehydroxymethylepoxyquinomicin DV Starenki, H Namba, VA Saenko, A Ohtsuru, S Maeda, K Umezawa, ... Clinical cancer research 10 (20), 6821-6829, 2004 | 121 | 2004 |
| Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells D Starenki, SK Hong, RV Lloyd, JI Park Oncogene 34 (35), 4624-4634, 2015 | 91 | 2015 |
| Molecular mechanisms of the effects of low concentrations of taxol in anaplastic thyroid cancer cells VM Pushkarev, DV Starenki, VA Saenko, H Namba, J Kurebayashi, ... Endocrinology 145 (7), 3143-3152, 2004 | 85 | 2004 |
| A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase PK Wu, SK Hong, S Veeranki, M Karkhanis, D Starenki, JA Plaza, JI Park Molecular and Cellular Biology, 2013 | 83 | 2013 |
| Obesity diminishes response to PD-1-based immunotherapies in renal cancer SK Boi, RM Orlandella, JT Gibson, WJ Turbitt, G Wald, L Thomas, ... Journal for immunotherapy of cancer 8 (2), 2020 | 73 | 2020 |
| Inhibition of nuclear factor-κB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells D Starenki, H Namba, V Saenko, A Ohtsuru, S Yamashita The Journal of Clinical Endocrinology & Metabolism 89 (1), 410-418, 2004 | 60 | 2004 |
| Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo D Starenki, JI Park The Journal of Clinical Endocrinology & Metabolism 98 (4), 1529-1540, 2013 | 59 | 2013 |
| Mortalin (GRP75/HSPA9) promotes survival and proliferation of thyroid carcinoma cells D Starenki, N Sosonkina, SK Hong, RV Lloyd, JI Park International journal of molecular sciences 20 (9), 2069, 2019 | 56 | 2019 |
| Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells Z Meng, N Mitsutake, M Nakashima, D Starenki, M Matsuse, S Takakura, ... Endocrinology 149 (11), 5357-5365, 2008 | 54* | 2008 |
| The role of STAT3 in thyroid cancer N Sosonkina, D Starenki, JI Park Cancers 6 (1), 526-544, 2014 | 50 | 2014 |
| Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer DW Doo, S Meza-Perez, AI Londoño, WN Goldsberry, AA Katre, ... Therapeutic advances in medical oncology 12, 1758835920913798, 2020 | 41 | 2020 |
| Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1 TR McCaw, M Li, D Starenki, M Liu, SJ Cooper, RC Arend, A Forero, ... Cancer Immunology, Immunotherapy 68, 2081-2094, 2019 | 36 | 2019 |
| Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability PK Wu, SK Hong, D Starenki, K Oshima, H Shao, JE Gestwicki, S Tsai, ... Oncogene 39 (21), 4257-4270, 2020 | 35 | 2020 |
| Inhibition of ABL tyrosine kinase potentiates radiation-induced terminal growth arrest in anaplastic thyroid cancer cells A Podtcheko, A Ohtsuru, H Namba, V Saenko, D Starenki, I Palona, ... Radiation Research 165 (1), 35-42, 2006 | 34 | 2006 |
| The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth TR McCaw, M Li, D Starenki, SJ Cooper, M Liu, S Meza-Perez, RC Arend, ... Cancer Immunology, Immunotherapy 68, 175-188, 2019 | 32 | 2019 |
| Suppression of B-RafV600E melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone SK Hong, D Starenki, PK Wu, JI Park Cancer biology & therapy 18 (2), 106-114, 2017 | 29 | 2017 |
| Pediatric medullary thyroid carcinoma D Starenki, JI Park Journal of pediatric oncology 3 (2), 29, 2015 | 28 | 2015 |
| Effects of low and high concentrations of antitumour drug taxol in anaplastic thyroid cancer cells VM Pushkarev, DV Starenki, VA Saenko, S Yamashita, OI Kovzun, ... Experimental Oncology, 2009 | 28 | 2009 |
| powerTCR: A model-based approach to comparative analysis of the clone size distribution of the T cell receptor repertoire H Koch, D Starenki, SJ Cooper, RM Myers, Q Li PLoS computational biology 14 (11), e1006571, 2018 | 25 | 2018 |
